Amneal Pharmaceuticals
AMRX
153 hedge funds and large institutions have $316M invested in Amneal Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 48 increasing their positions, 51 reducing their positions, and 23 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.61% less ownership
Funds ownership: 66.51% → 65.9% (-0.61%)
6% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 51
9% less funds holding
Funds holding: 168 → 153 (-15)
24% less capital invested
Capital invested by funds: $417M → $316M (-$101M)
39% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 23
78% less call options, than puts
Call options by funds: $547K | Put options by funds: $2.49M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.69M |
| 3 |
BlackRock
New York
|
+$1.35M |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$1.35M |
| 5 |
HF
HRT Financial
New York
|
+$949K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
-$2.53M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$1.83M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$1.46M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$1.4M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$804K |
AMRX Hedge Fund Activity: Q2 2022 in Review
153 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q2 2022, worth a combined $316M — down 24% from $417M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of AMRX and 14 opened new positions — a net loss of 9 holders — while 51 trimmed existing stakes and 48 added.
The largest buyer was Millennium Management, adding an estimated $2.8M. The largest seller was Nuveen, cutting an estimated $2.53M.
- 153 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q2 2022, down from 168 in Q1 2022.
- Funds reported $316M of Amneal Pharmaceuticals stock for Q2 2022, down 24% quarter-over-quarter.
- 14 funds opened new Amneal Pharmaceuticals positions in Q2 2022 and 23 closed out, a net change of -9 holders.
- The largest Amneal Pharmaceuticals buyer in Q2 2022 was Millennium Management, an estimated $2.8M added.
- The largest Amneal Pharmaceuticals seller in Q2 2022 was Nuveen, an estimated $2.53M sold.
Based on aggregated 13F filings for Q2 2022.